The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•20 March 2026•

1 min read

Gilead Exercises Option for Assembly Biosciences' HPI Program in $35M Deal

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Gilead Sciences licensed Assembly Biosciences' HPI program, triggering a $35 million payment.

2There is potential for up to $330 million in additional milestone payments based on development and regulatory achievements.

Version History

1 additional source confirmed this story

Gilead Sciences has officially opted into the Helicase-Primase Inhibitor (HPI) program developed by Assembly Biosciences, triggering an immediate $35 million payment. The agreement includes potential future milestone payments of up to $330 million, contingent upon achieving specific development and regulatory goals. This strategic move follows encouraging preclinical and early clinical data, reinforcing the collaborative efforts between the two biotech firms. Clinical progress is expected to continue with Phase 2 trials for both HPI and HDV (ABI-6250) candidates slated to begin by late 2026. For Assembly Biosciences, the deal provides essential non-dilutive capital and validates its research platform through a partnership with a major industry player. While the timeline for clinical results extends into 2026, the partnership underscores a significant long-term commitment to advancing viral disease treatments.